MetaVia Inc. (MTVA)

MetaVia's stock experienced several events in the past six months. Top-line data from the Phase 1 trial for DA-1726 was expected in Q4 2025. The company reported its Q2 2025 financial results, noting $17.6 million in cash and an AI-driven collaboration with Syntekabio for DA-1241. The stock surged following an announcement of an AI breakthrough. Despite positive clinical highlights, the stock declined on the day of the Q3 2025 financial results announcement. Positive Phase 2a data on Vanoglipel (DA-1241) for MASH was presented at AASLD The Liver Meeting® 2025. MetaVia announced a 1-for-11 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and successfully regained compliance. Positive results were reported from the Phase 1b clinical trial of DA-1726. The share price declined by 63.72% from January 2, 2025, to December 31, 2025.

As a clinical-stage biotechnology company without commercialized products, MetaVia, Inc. does not have traditional demand seasonality. Demand is driven by clinical trial outcomes, regulatory milestones, and investor interest rather than seasonal consumer purchasing patterns.

MetaVia, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. Their primary product candidates include DA-1726, a GLP1R and GCGR dual agonist for obesity in Phase 1 clinical trials, and DA-1241 (vanoglipel), a GPR119 agonist for MASH and T2DM in Phase 2a clinical trials. The company has partnerships with Pfizer Inc. for Gemcabene and Dong-A ST for manufacturing and R&D. MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name in November 2024.

MetaVia, Inc. is headquartered in Cambridge, Massachusetts, and incorporated in Delaware. Its operations are primarily within the United States.

MetaVia's brand reputation has been influenced by its rebranding, positive clinical trial results, Nasdaq compliance issues, a reverse stock split, an AI breakthrough, and stock performance. The name change and focus on cardiometabolic diseases aimed to refine its corporate identity. Positive data from clinical trials for DA-1726 and DA-1241 bolstered its scientific reputation. A Nasdaq non-compliance notice negatively impacted investor confidence, but compliance was regained. The reverse stock split had a potentially negative perception. An AI breakthrough led to a stock surge. The stock experienced a significant decline, which may have affected investor sentiment.

MetaVia, Inc. has a significant portion of its shares held by institutional and individual owners. 28 institutional owners hold a total of 488,207 shares. Major institutional shareholders include Vanguard Group Inc., Geode Capital Management, Llc., and Dong-A ST Co., Ltd. Approximately 63.0% of the company's outstanding shares are owned by corporate insiders, including Dong-A ST Co., Ltd.